# Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer

> **NCT01196429** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 90 (actual)

## Conditions studied

- Ovarian Clear Cell Cystadenocarcinoma
- Stage III Ovarian Cancer
- Stage IV Ovarian Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Docetaxel
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT01196429
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2019-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01196429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01196429, "Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01196429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*